Research programme: autism therapeutic - Innovation Pharmaceuticals

Drug Profile

Research programme: autism therapeutic - Innovation Pharmaceuticals

Alternative Names: Autism compound - Innovation Pharmaceuticals; KM-391

Latest Information Update: 09 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Innovation Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Serotonin uptake modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Autistic disorder

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 16 May 2012 Preclinical development is ongoing for Austistic disorder in USA
  • 28 Mar 2011 Cellceutix signs a Confidential Disclosure Agreement with an undisclosed pharmaceutical company for the development of KM-391 in Autism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top